Research Autopsy Program to Study Cancer Evolution Metastasis

Research Autopsy Program to Study Cancer Evolution, Metastasis, and Drug Resistance Julie Reeser, Ph. D October 2020 Team: Reeser, Julie, Wing, Michele, Krook, Melanie, Bonneville, Russell, Paruchuri, Anoosha, Dao, Thuy, Smith, Amy, Samorodnitsky, Eric, Hoskins, Emily, Thomas, Diana, Freud, Aharon, Shields, Peter, Carbone, David, Liebner, David, Cole, Sharon, Otterson, Gregory, Hays, John, Noonan, Anne, Yu, Lianbo, Allenby, Patricia, Chen, Hui-zi, Roychowdhury, Sameek The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Establishing research autopsy at OSU to study advanced cancer § We have built a multi-disciplinary team to study advanced metastatic cancer via research autopsy. § Patients with metastatic cancer consented for body donation for cancer research. § Limited rapid research autopsy completed within 2 -24 hours postmortem. § Tumors and adjacent normal extensively sampled from multiple sites. § 51 research autopsies performed since opening our program in September 2016. § Here, we highlight some of these studies 2

Tumor heterogeneity and acquired drug resistance in FGFR 2 -fusion positive cholangiocarcinoma through rapid research autopsy 3 Krook MA et al, Cold Spring Harbour Molecular Case Studies 2019

Research autopsy demonstrates polyclonal acquired resistance in a patient with metastatic gastrointestinal stromal tumor 4 Paruchuri A et al, JCO Precision Oncology 2019

Additional Publications and Ongoing Projects: § Chen H et al, “Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy, ” Oncotarget 2019, published § Krook MA et al, “Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity, ” Trends in Cancer 2019, published § Chen H et al, Cohorts of small cell lung carcinoma (N=5 from OSU, N=3 from Moffitt), in preparation § Krook MA et al, Cohort of cholangiocarcinoma (N=18), undergoing analyses § Pilot Projects, pending funding availability, in other cancer types in 2021 § Krook MA et al, “Focused FGFR sequencing permits fusion monitoring in serial cf. DNA and reveals an expanded landscape of FGFR resistance mutations through rapid research autopsy, ” Precision Oncology 2020, in revision (benchmarking cf. DNA assay using autopsy tissues) 5

THANK YOU!